Across TCGA pan-cancer cohorts, IFNL3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IFNL3 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher IFNL3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFNL3 expression acts as an unfavorable survival marker.

KIRC and COAD are the cancer types where IFNL3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.180	0.796	.001	30	view →
COAD	DFS	Median	All	0.194	0.688	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IFNL3 tumor-vs-normal RNA expression · all IFNL3 data types